Cognition Therapeutics(CGTX) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update - End-of-Phase 2 meeting with FDA requested for Alzheimer's disease – - Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC – - Two posters at ARVO describe zervimesine's role supporting retinal cell health - Purchase, NY – May 7, 2025 – Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that t ...